CAR.70/IL15-transduced CB-NK cells / UT MD Anderson Cancer Center - LARVOL DELTA

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies (clinicaltrials.gov) - P1/2 | N=42 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma (clinicaltrials.gov) - P1/2 | N=50 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial primary completion date: Sep 2025 ➔ Sep 2027

Trial primary completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Lung Cancer • Mesothelioma • Oncology • Osteosarcoma • Renal Cell Carcinoma • Sarcoma • Solid Tumor • PD-L1

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies (clinicaltrials.gov) - P1/2 | N=42 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

New P1/2 trial • Oncology

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances (clinicaltrials.gov) - P1/2 | N=94 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Aug 2023 ➔ Aug 2026 | Trial primary completion date: Aug 2023 ➔ Aug 2026

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma (clinicaltrials.gov) - P1/2 | N=50 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Lung Cancer • Mesothelioma • Oncology • Osteosarcoma • Renal Cell Carcinoma • Sarcoma • Solid Tumor • PD-L1

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

Metastases • New P1/2 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Lung Cancer • Mesothelioma • Oncology • Osteosarcoma • Renal Cell Carcinoma • Sarcoma • Solid Tumor • PD-L1

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances (clinicaltrials.gov) - P1/2 | N=94 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology